Review Article

Recent advancements in hematopoietic stem cell transplantation in Taiwan

Chi-Cheng Li[a,b,c], Xavier Cheng-Hong Tsai[d,e,f], Wei-Han Huang[a,b,g], Tso-Fu Wang[a,c]*

[a]Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, [b]Center of Stem Cell and Precision Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, [c]School of Medicine, Tzu Chi University, Hualien, Taiwan, [d]Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, [e]Genome and Systems Biology Degree Program, National Taiwan University, Taipei, Taiwan, [f]Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, [g]Department of Clinical Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

ABSTRACT

Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone's experience and promote the advances of HSCT in Taiwan to gather everyone's experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival. In Taiwan, transplant donors showed remarkable growth from unrelated (24.8%) and haploidentical (10.5%) donors. The number of older patients (17.4%; aged ≥61 years) who underwent transplantation has increased markedly. This review summarizes several significant developments in HSCT treatment in Taiwan. First, the use of Anti-thymocyte globulin (ATG) and intravenous busulfan regimens were important risk factors for predicting hepatic sinusoidal obstruction syndrome. Second, a new, machine learning-based risk prediction scoring system for posttransplantation lymphoproliferative disorder has identified five risk factors: aplastic anemia, partially mismatched related donors, fludarabine use, ATG use, and acute skin graft-versus-host disease. Third, although the incidence of idiopathic pneumonia syndrome was low (1.1%), its mortality rate was high (58.1%). Fourth, difficult-to-treat mantle cell and T-cell lymphomas treated with autologous HSCT during earlier remission had higher survival rates. Fifth, treatment of incurable multiple myeloma with autologous HSCT showed a median progression-free survival and overall survival of 46.5 and 70.4 months, respectively. Sixth, different haploidentical transplantation strategies were compared. Seventh, caution should be taken in administering allogeneic HSCT treatment in older patients with myeloid leukemia with a Charlson Comorbidity Index ≥3 because of a higher risk of nonrelapse mortality.

KEYWORDS: *Allogeneic, Autologous, Hematopoietic stem cell transplantation, Taiwan*

INTRODUCTION

*H*ematopoietic stem cell transplantation (HSCT) is an important treatment option for patients with benign or malignant hematological disorders [1]. To date, more than one million HSCTs have been performed worldwide, including autologous (auto-) and allogeneic (allo-) types [2]. The Taiwan Society of Blood and Marrow Transplantation (TBMT) was initiated in 1992 as a nationwide gathering to foster communication and learning on HSCT. The founding purpose of TBMT is to provide a robust platform for academic discussion, clinical research, and ongoing education for physicians specializing in transplantation and medical personnel working in related fields. Currently, TBMT comprises 932 members, including physicians, nurses, other comedical professionals, and clinical coordinators. The core TBMT activities include organizing an annual congress and quarterly workshop/meeting, publishing bimonthly TBMT E-communication, collecting clinical data of transplant patients, publishing the Annual Report of the Nationwide Survey for transplant recipients, promoting more than 12 working groups, and publishing several guidelines for HSCT.

The Taiwan Blood and Marrow Transplantation Registry (TBMTR), which is operated and maintained by the TBMT, collects HSCT data to gather everyone's experience and promote advances of HSCT in Taiwan. From 1983 to 2022, a cumulative total of 10,236 HSCTs were performed in Taiwan, as illustrated in Figure 1, which signifies a substantial

*Address for correspondence: Dr. Tso-Fu Wang, Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Section 3, Chung-Yang Road, Hualien, Taiwan.
E-mail: tfwang@tzuchi.com.tw

Access this article online

Quick Response Code:

Website: www.tcmjmed.com

DOI: 10.4103/tcmj.tcmj_276_23

Figure 1: Cumulative numbers of patients receiving hematopoietic stem cell transplantation in Taiwan

milestone. In the past 10 years, the number of HSCT Transplant centers has burgeoned from 14 to 23, making the maturation and widespread adoption of HSCT as a therapeutic procedure for patients with hematologic diseases in Taiwan. This review discusses the outcomes of transplantation in Taiwan and highlights the advancements in HSCT based on data from the TBMTR database.

UPDATE ON TRANSPLANTATION OUTCOMES IN TAIWAN UNTIL 2022

Clinical information on HSCTs in Taiwan has been recorded in the TBMTR since 2009 and is reported annually. As of 2022, 7,390 transplants had been analyzed [3]. Of these, 4078 (55.2%) and 3312 (44.8%) cases were allogeneic and autologous, respectively. The four leading indications for transplantation are acute myeloid leukemia (AML, 25.6%), non-Hodgkin lymphoma (22.7%), multiple myeloma (MM, 18.8%), and acute lymphoblastic leukemia (11.4%). In total, 1283 older patients (aged ≥61 years; 17.4%) underwent various types of HSCT. Compared to 2009–2017, patients with age ≥61 increased from 14.0% to 21.8% in 2018–2022. The different age groups of all patients who underwent HSCT are shown in Figure 2. Of the transplant donors, 44.8% were autologous, 19.9% were human leukocyte antigen (HLA)-matched siblings, 24.8% were unrelated donors (including cord blood), and 10.5% were HLA-mismatched, mainly haploidentical related donors [Figure 3]. Notably, because of the low birthrate and fewer children per family in Taiwanese society, the proportion of unrelated donors exceeds that of matched siblings. In 1993, the Buddhist Tzu Chi Stem Cells Center, which is affiliated with the Buddhist Tzu Chi Foundation, established an independent, compassion-based bone marrow stem cell registry in Taiwan. It has provided >6,000 unrelated hematopoietic stem cell donors worldwide and maintains a donor pool of approximately 450,000 per year [4]. As the improvement of prophylaxis and treatment of graft-versus-host disease (GvHD), and posttransplant care, transplantations using mismatched donors increased from 8% in 2009–2017 to 17.5% in 2018–2022. The rise in elderly patients and mismatched transplants collectively represent the evolving landscape and progression of HSCT in Taiwan.


Figure 2: Ages at hematopoietic stem cell transplantation in Taiwan

Auto-HSCT and allo-HSCT are associated with a median overall survival (OS) of 11.15 years (95% confidence interval [CI]: 10.25–not estimable [NE]) and 3.68 years (95% CI: 2.85–4.63), respectively [Figure 4]. The cumulative 30- and 100-day mortality rates for auto-HSCT were 1.0% and 3.4%, respectively, whereas those for allo-HSCT were 3.2% and 12.2%, respectively [Figure 5]. Notably, the median OS of HSCTs performed using HLA-matched unrelated donors tended to be higher than that of HSCTs performed using matched sibling donors (7.68 years [95% CI: 6.02–NE] vs. 4.28 years [95% CI: 3.11-5.76]; P = 0.05). This is attributable to the introduction of antithymocyte globulin (ATG) in Taiwan, which has been covered by the National Health Insurance since 2001. The subsequent widespread use of ATG as prophylaxis for GvHD in unrelated donor transplants has significantly reduced the incidence of severe acute and chronic GvHD. Moreover, the universal use of high-resolution HLA typing to identify suitable unrelated donors has been crucial. Among benign hematological disorders, severe aplastic anemia is most indicated for allo-HSCT. The TBMTR records 249 cases of severe aplastic anemia, and the median OS across age groups has not yet been reached. The distribution of 95% CI shows NE–NE in age ≤20 years; NE–NE in 20 <age ≤40; NE–NE in 40 < age ≤50, 0.69–NE in 50 < age ≤60, and 0.86–NE in age >60. Of 7390 patients who underwent transplantation, 214 (2.9%) developed secondary malignancies, the most common of which are posttransplant lymphoproliferative disorders (PTLD) and solid tumors. Of those who underwent allo- and auto-HSCT, 1,441 (35.3%)

**Figure 3:** Types of hematopoietic stem cell transplantation in Taiwan

Figure 4: Overall survival of patients receiving either auto-hematopoietic stem cell transplantation (HSCT) or allo-HSCT. HSCT: Hematopoietic stem cell transplantation. HSCT: Hematopoietic stem cell transplantation


Figure 5: The cumulative 30-, 60-, and 100-day mortalities of patients receiving either auto-hematopoietic stem cell transplantation (HSCT) or allo-hematopoietic stem cell transplantation

and 656 (19.8%) died, respectively, with disease relapse as the main cause of death (49.5% and 57.9%, respectively).

SPECIAL HEMATOPOIETIC STEM CELL TRANSPLANTATION ADVANCEMENTS IN TAIWAN
Liver sinusoidal obstruction syndrome/veno-occlusive disease

Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is an unpredictable and potentially life-threatening complication of HSCT [5,6]. Clinically, hepatic SOS/VOD is characterized by fluid retention, weight gain, ascites, hyperbilirubinemia, and painful hepatomegaly in the absence of other identifiable causes of liver disease. It most commonly occurs in the first 20 days after transplantation [7,8]. The pathophysiology of SOS/VOD involves primary toxic injury of sinusoidal endothelial cells caused by high-dose chemotherapy or radiation, which leads to central venous occlusion and sinusoidal obstruction [9,10]. The incidence of hepatic SOS/VOD varies widely, ranging from 0% to 60%, and mortality and multiple organ failure rates can be as high as 80% [11,12].

Lee *et al.* [13] analyzed the 2009–2014 TBMTR records and found that of the 2,345 patients who underwent transplantation, 39 (1.66%) developed hepatic SOS/VOD, with auto-HSCT and allo-HSCT accounting for 0.1% and 2.87% of these cases, respectively [Table 1] [13]. Multivariate analysis identified chronic hepatitis C virus infection (hazard ratio [HR]: 6.38, 95% CI: 1.89–21.47), ATG (rabbit) use (HR: 4.69, 95% CI: 2.02–10.86), diagnosis of myelodysplastic syndrome (MDS; HR: 3.10, 95% CI: 1.18–8.14), and intravenous busulfan administration (HR: 2.62, 95% CI: 1.23–5.56) as independent predictors of a higher risk for hepatic SOS/VOD. The overall mortality rate was 79.5%. Thus, this cohort study provides important data on the incidence of hepatic SOS/VOD and its risk factors.

Establishing new risk prediction scores for posttransplant lymphoproliferative disorders using machine learning

PTLD is a potentially lethal allo-HSCT complication that is typically associated with Epstein–Barr virus reactivation and infection resulting from HSCT-induced immunosuppression [14-16]. Although the mortality rate has historically been as high as 80%–90% [17,18], recent studies indicate that outcomes can improve significantly with frequent monitoring for circulating Epstein–Barr virus DNAemia and prompt treatment with rituximab, prompt immunosuppressant tapering, or adoptive immunotherapy [19,20]. Thus, identification of those at a high risk of developing PTLD and early intervention are crucial.

In 2019, using data from the Japanese national transplant registry, Fujimoto *et al.* [21] proposed a scoring system for PTLD prediction after allo-HSCT and identified three risk factors: ATG use (high dose = 2 points; low dose = 1 point), donor type (HLA-mismatched related donor = 1 point; unrelated donor = 1 point; cord blood = 2 points), and a diagnosis of aplastic anemia (1 point). The study classified risk into the following categories: low risk (0–1 points), intermediate risk (2 points), high risk (3 points), and very high risk (4–5 points).

A 2021 analysis of the TBMTR database by Lee *et al.* [22] revealed that of the 2,148 cases that underwent allo-HSCT between 2009 and 2018, 57 (2.65%) developed PTLD. In this group, based on the Fujimoto scoring system, the probability of developing PTLD after 5 years was 1.15%, 3.06%, 4.09%, and 8.97% for the low-, intermediate-, high-, and very high-risk groups, respectively. Furthermore, acceptable discrimination was determined as a C-statistic of 0.65. However, based on the same data, Lee *et al.* used machine learning to develop a superior risk prediction scoring system. Compared with the Fujimoto system, the machine-learning algorithm (least absolute shrinkage and selection operator [LASSO]) identified additional risk factors, including fludarabine use in the

conditioning regimen and the development of acute GvHD with skin involvement [Table 2]. Lee's LASSO prediction model stratified patients into low-risk (0–3 points; *n* = 771), intermediate-risk (4–6 points; *n* = 971), high-risk (7–8 points; *n* = 321), and very high-risk (9–12 points; *n* = 85) groups. Of the 57 patients reported with PTLD, the probability of developing low-, intermediate-, high-, or very high-risk PTLD was 0.52%, 2.47%, 5.92%, and 11.76%, respectively. Compared with patients in the low-risk group, the odds ratio revealed that patients in the intermediate-, high-, and very high-risk groups had 5, 12, and 26 times greater odds of developing PTLD, respectively, which was significantly superior to the findings of the Fujimoto system. Moreover, Lee's LASSO scoring system yielded an optimism-corrected area under the curve of 0.75 (95% CI: 0.69–0.81), which was higher than that obtained using the Fujimoto scoring system (0.65, 95% CI: 0.59–0.72), indicating better discrimination.

Altogether, these observations demonstrate that the TBMTR-based LASSO model is an effective system for predicting and scoring PTLD.

Incidence and predictors of idiopathic pneumonia syndrome after hematopoietic stem cell transplantation

Idiopathic pneumonia syndrome (IPS) is a rare but deadly complication of HSCT [23,24]. Its pathogenesis is multifactorial and includes direct pulmonary endothelial cell damage by conditioning toxicity and indirect damage through the activation of the host inflammatory response, which results in pulmonary surfactant disruption, capillary leakage, pulmonary edema, and alveolar epithelial injury [25,26]. IPS is diagnosed based on exclusion. It is characterized by progressive respiratory distress with signs and symptoms of diffuse pneumonitis in the absence of evidence of infection, cardiac dysfunction, acute renal failure, or iatrogenic fluid overload as the underlying etiology [27]. The incidence of IPS after HSCT varies from 2% to 17% [26,28-32], and its mortality rate is >60% [33,34].

In 2022, Liu *et al.* [35] analyzed the 2009–2019 TBMTR data to determine the outlook of IPS in Taiwan. They found that of 3,924 patients who underwent HSCT, 43 (1.1%) were diagnosed with IPS. Compared with allo-HSCT, auto-HSCT was associated with a lower IPS incidence (0.68% vs. 1.44%, respectively; *P* = 0.022). Multivariate analysis revealed the use of total body irradiation or intravenous busulfan in the conditioning regimen as independent predictors of IPS. The overall mortality rate was 58.1% in our cohort. Thus, early IPS detection and prompt treatment can improve patient outcomes.

Stem cell transplantation for mantle cell and T-cell lymphoma

Mantle cell lymphoma (MCL) and T-cell lymphoma (except for anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma [ALCL]) are difficult to treat with conventional chemotherapy [36-38]. These lymphomas are generally aggressive and relapse frequently. Although SCT can improve survival, most studies on these lymphomas have been conducted in Western countries and Japan [39-42]. Nonetheless, two important Taiwanese studies based on the TBMTR database have been reported.

Table 1: Incidence of hepatic veno-occlusive disease

Patient characteristics	Number with hepatic VOD/number evaluated (incidence %)	*P*
Whole cohort	39/2345 (1.66)	
Adult patients (age ≥18 year old)	33/2130 (1.55)	0.1749
Pediatric patients (age <18 year old)	6/215 (2.79)	
Autologous HSCT	1/1018 (0.10)	<0.0001
Allogeneic HSCT	38/1326 (2.87)	
HLA-matched unrelated donor	13/289 (4.50)	<0.0001
HLA-mismatched unrelated donor	10/387 (2.58)	
HLA-matched sibling	13/552 (2.36)	
HLA partial mismatched related donor	2/66 (3.03)	
Haplotype donor	0/25 (0.00)	
BM graft	0/84 (0.00)	0.4917
PBSC graft	38/2223 (1.71)	
Umbilical cord blood	1/26 (3.85)	

PBSC: Hematopoietic stem cell transplantation, BM: Blood and marrow, HLA: Human leukocyte antigen, VOD: Veno-occlusive disease, HSCT: Hematopoietic stem cell transplantation

Table 2: Predictive model using least absolute shrinkage and selection operator regression

Predictors	OR (95% CI)	*P*	Lee's LASSO score
Aplastic anemia	2.14 (1.00–4.56)	0.050	2
Partially-mismatched related donor marrow	2.94 (1.49–5.80)	0.002	3
Use of fludarabine	1.71 (0.97–3.00)	0.062	1
Use of ATG	6.45 (2.3–18.08)	<0.001	4
Acute GVHD with skin involvement	1.76 (1.02–3.03)	0.044	2
Total score			12

LASSO: Least absolute shrinkage and selection operator, ATG: Anti-thymocyte globulin, GVHD: Graft-versus-host disease, CI: Confidence interval, OR: Odds ratio

International guidelines recommend early consolidative auto-HSCT for eligible patients with MCL, whereas allo-HSCT is reserved for the treatment of refractory cases. Wang *et al.* [43] analyzed the post-HSCT outcomes of 99 patients with MCL between 1999 and 2020 in Taiwan. Overall, 94 patients underwent auto-HSCT, 13 underwent allo-HSCT (including eight after auto-HSCT failure). Forty-nine (52.1%) patients who underwent auto-HSCT during their first complete remission (CR1) exhibited longer survival than those who were not in CR1 (progression-free survival [PFS]: 50.8 vs. 31.3 months, $P = 0.084$; OS: Not reached vs. 66.8 months, $P = 0.013$). Multivariate analysis identified blastoid variant MCL, transplantation not in CR1, and disease progression within 12 months after auto-HSCT as independent predictors of inferior OS.

Hsu *et al.* [44] surveyed 131 patients with T-cell lymphoma who underwent auto-HSCT ($n = 90$) or allo-HSCT ($n = 41$) in 2009–2014 in Taiwan. Their analysis revealed that patients with extranodal natural killer/T-cell lymphoma had the worst outcomes, with a 2-year OS rate of 23.5%. The OS rates for the other major subtypes of T-cell lymphoma, ALCL, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma not otherwise specified, were 72.9%, 75.0%, and 51.4%, respectively. Most auto-HSCT patients had ALCL or were in CR, whereas most allo-HSCT recipients had advanced disease. Auto- and allo-HSCT had 2-year OS rates of 62.6% (95% CI: 51.0%–74.2%) and 47.2% (95% CI: 30.2%–64.2%), respectively. Patients who were in CR1 before transplantation obtained the best outcomes.

Autologous stem cell transplantation for the treatment of multiple myeloma

MM is a monoclonal plasma cell malignancy with traditionally low cure rates. Despite the development of numerous nonchemotherapeutic agents, induction therapy with novel agents, followed by upfront high-dose therapy and auto-HSCT, is still recommended for newly diagnosed, transplantation-eligible patients with MM [45,46]. Although the incidence of MM in Taiwan is lower than that in Western countries, it has increased from 0.75 to 1.83 persons per 100,000 people (mean age at diagnosis: 68.7 years) [47]. A higher prevalence of extramedullary myeloma in patients aged 55 years has also been reported [48].

Huang *et al.* [49] analyzed data on 396 patients with MM in the TBMTR database who underwent auto-HSCT from 2006 to 2015 to determine treatment efficacy and identify prognostic factors. In this transplant cohort, 61.9%, 23.7%, and 14.4% of the patients had Durie–Salmon disease stages III, II, and I, respectively. The median PFS and OS after auto-HSCT were 46.5 and 70.4 months, respectively. Compared with Durie–Salmon stages I and II, stage III was a poor prognostic factor, affecting both PFS and OS ($P = 0.006$ and 0.028, respectively) [Table 3]. In addition, patients with better treatment responses before transplantation had better PFS and OS than those who did not exhibit responses (both $P < 0.0001$). The overall incidence of transplantation-associated organ toxicity is low in Taiwan.

Haploidentical transplantation strategies in Taiwan

Because of the limited availability of HLA-matched related or unrelated donors, the use of haploidentical related donors for HSCT (haplo-HSCT) is rapidly increasing worldwide. Successful haplo-HSCT requires the adjustment of T-cell alloreactivity and induction of T-cell tolerance to allow engraftment and reduce GvHD. The main strategies for achieving this are the use of posttransplantation cyclophosphamide (PTCy) with or without ATG [50-56], administration of high-dose cyclophosphamide following graft infusion; and the use of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow plus peripheral blood stem cells (GIAC: G-CSF mobilization, intensified posttransplantation immunosuppression, ATG to prevent GvHD and aid engraftment, and the combination of bone marrow and peripheral blood stem cell graft) [57-59]. However, a direct comparison of these two approaches is lacking. In Taiwan, the original GIAC has been modified into the simpler mGIAC, which retains the use of ATG and G-CSF-primed bone marrow plus peripheral blood stem cell graft but combines them with the more commonly available fludarabine-based conditioning regimens. Tsai *et al.* [60] analyzed the data recorded in the

Table 3: The univariate and multivariate cox regression analyses regarding overall survival for multiple myeloma patients after autologous stem cell transplantation

Factors	Univariate			Multivariate		
	HR	95% CI	*P*	HR	95% CI	*P*
Durie salmon stage						
Stage I			0.051			0.090
Stage II	3.723	1.077–12.875	0.038	3.489	1.003–12.140	0.049
Stage III	4.241	1.326–13.567	0.015	3.728	1.151–12.071	0.028
Response before ASCT						
sCR			<0.0001			<0.0001
CR	0.778	0.219–2.760	0.698	0.690	0.192–2.480	0.569
VGPR	0.744	0.220–2.515	0.635	0.680	0.200–2.309	0.536
PR	1.237	0.370–4.134	0.730	1.034	0.306–3.495	0.958
SD	1.503	0.371–6.088	0.568	1.312	0.321–5.359	0.705
PD	10.792	2.407–48.393	0.002	9.367	2.059–42.616	0.004
Infection	2.127	1.225–3.694	0.007	2.186	1.184–4.036	0.012

ASCT: Autologous stem cell transplantation, CR: Complete response, sCR: Stringent CR, PR: Partial response, VGPR: Very good PR, SD: Stable disease, PD: Progressive disease, CI: Confidence interval, HR: Hazard ratio

TBMTR database from 2011 to 2019 and compared the transplantation outcomes of mGIAC, PTCy with ATG, and PTCy without ATG. The clinical characteristics of the patients are shown in Table 4.

Tsai *et al*. found that the three approaches had equivalent 60-day neutrophil engraftment rates (mGIAC: 99.3%; PTCy with ATG: 97.6%; and PTCy without ATG: 92.3%; $P = 0.113$). However, they differed significantly in neutrophil engraftment times (median: 12 days vs. 15 days vs. 17 days, respectively; $P < 0.001$). Moreover, the 100-day platelet engraftment

rates (94.2% vs. 90.5% vs. 68.2%, respectively; $P = 0.001$) and platelet engraftment times (median: 18 days vs. 25 days vs. 32 days, respectively; $P < 0.001$) differed significantly. The cumulative incidences of grade III–IV GvHD at 100 days were similar among the three groups (16.4% vs. 14.3% vs. 11.5%, respectively; $P = 0.728$). However, mGIAC showed significantly higher, more extensive chronic GvHD 2-year cumulative incidences (38.8% vs. 8.7% vs 18.6%, respectively; $P = 0.020$). Furthermore, mGIAC attained the most favorable 2-year OS (48.9% vs. 38.1% vs. 22.0%, respectively; $P < 0.001$). Patients with low/intermediate risk at the time of

Table 4: Comparison of clinical characteristics among patients with different haplo-hematopoietic stem cell transplantation approaches

Variables	Total (*n*=178), *n* (%)	Modified GIAC (*n*=110, 61.8%), *n* (%)	PTCy without ATG (*n*=26, 14.6%), *n* (%)	PTCy with ATG (*n*=42, 23.6%), *n* (%)	*P*
Sex					
Male	88 (49.4)	52 (47.3)	12 (46.2)	24 (57.1)	0.518
Female	90 (50.6)	58 (52.7)	14 (53.8)	18 (42.9)	
Age (years)	45.2 (18.7–75.6)	42.3 (18.7–69.2)	50.1 (21.8–75.6)	49.4 (18.9–68.3)	0.098
Disease					
AML	106 (59.6)	65 (59.1)	13 (50.0)	28 (66.7)	0.391
MDS	11 (6.2)	9 (8.2)	0	2 (4.8)	0.270
MDS/MPN	5 (2.8)	1 (0.9)	3 (11.5)	1 (2.4)	0.013
ALL	32 (18.0)	24 (21.8)	3 (11.5)	5 (11.9)	0.237
MPAL	2 (1.1)	2 (1.8)	0	0	0.535
CML	6 (3.4)	3 (2.5)	1 (3.8)	2 (4.8)	0.816
NHL	12 (6.7)	3 (2.7)	6 (23.1)	3 (7.1)	0.001
HL	3 (1.7)	2 (1.8)	0	1 (2.4)	0.748
Myeloma	1 (0.6)	1 (0.9)	0	0	0.733
Conditioning					
Myeloablative	53 (29.8)	25 (22.7)	10 (38.5)	18 (42.9)	0.229
Reduced intensity	125 (70.2)	85 (77.3)	16 (61.5)	24 (57.1)	
ATG dose per kilogram	6.0 (2.0–7.5)	6.0 (5.0–7.5)	0	4.0 (2.0–7.5)	<0.001
Stem cell source					
BM + mobilized PB	110 (61.8)	110 (100)	0	0	<0.001
Mobilized PB	68 (38.2)	0	26 (100)	42 (100)	
Donor relationship					
Child	85 (47.8)	46 (41.8)	17 (65.4)	22 (52.4)	0.106
Parent	43 (24.2)	33 (30.0)	2 (7.7)	8 (19.0)	
Sibling	50 (28.1)	31 (28.2)	7 (26.9)	12 (28.6)	
Donor–recipient sex combination					
Female donor to male recipient	47 (26.4)	30 (27.3)	5 (19.2)	12 (28.6)	0.659
Other combinations	131 (73.6)	80 (72.7)	21 (80.8)	30 (71.4)	
Donor–recipient CMV serostatus					
Negative–negative	3 (1.7)	1 (0.9)	1 (3.8)	1 (2.4)	0.073ᵞ
Negative–positive	40 (22.5)	23 (20.9)	11 (42.3)	6 (14.3)	
Positive–negative	11 (6.2)	9 (8.2)	1 (3.8)	1 (2.4)	
Positive–positive	121 (68.0)	77 (70.0)	12 (46.2)	32 (76.2)	
Missing	3 (1.7)	0	1 (3.8)	2 (4.8)	
CD34 (10^6/kg)	5.08 (1.3–21.2)	5.0 (2.2–8.5)	5.87 (3.0–20.7)	6.0 (1.3–21.2)	<0.001
Disease risk index					
Low	11 (6.2)	8 (7.3)	0	3 (7.1)	0.069
Intermediate	81 (45.5)	47 (42.7)	11 (42.3)	23 (54.8)	
High	71 (39.9)	46 (41.8)	15 (57.7)	10 (23.8)	
Very high	15 (8.4)	9 (8.2)	0	6 (14.3)	
Year of HSCT	2016 (2011–2019)	2016 (2012–2019)	2016 (2014–2019)	2016 (2011–2019)	0.980

ᵞP-values <0.05 were considered to be statistically significant MDS: Myelodysplastic syndrome, MPN: Myeloproliferative neoplasm, MPAL: Mixed phenotypic acute leukemia, CML: Chronic myeloid leukemia, HL: Hodgkin lymphoma, NHL: Non-HL, BM: Bone marrow, PB: Peripheral blood, CMV: Cytomegalovirus, HSCT: Hematopoietic stem cell transplantation, AML: Acute myeloid leukemia, ALL: Acute lymphocytic leukemia, ATG: Antithymocyte immunoglobulin, PTCy: Posttransplantation cyclophosphamide, GIAC: Global information assurance certification

Table 5: Survival analysis for elderly patients after allo-hematopoietic stem cell transplantation

Predictive variables	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P	HR (95% CI)	P
Age >60 years	1.030 (0.714–1.485)	0.875	1.029 (0.711–1.489)	0.881
Sex (male)	0.986 (0.698–1.392)	0.936	1.030 (0.728–1.457)	0.867
HLA mismatch	1.284 (0.814–2.026)	0.282		
Unrelated donor source	1.043 (0.736–1.476)	0.814		
First remission as transplantation	0.717 (0.493–1.042)	0.081	0.690 (0.469–1.016)	0.06
Myeloablative conditioning	1.193 (0.816–1.745)	0.362		
TBI based conditioning	1.335 (0.751–2.371)	0.325		
Charlson Comorbidity Index ≥3	1.590 (1.124–2.250)	0.009	1.889 (1.316–2.713)	0.001
Donor's age >50 year old	1.188 (0.830–1.700)	0.346		

TBI: Total body irradiation, HLA: Human leukocyte antigen, CI: Confidence interval, HR: Hazard ratio

transplantation who received mGIAC also demonstrated the best 2-year OS (72.7% vs. 51.1% vs. 22.7%, respectively; $P < 0.001$).

Recent progress in PTCy-based protocols, which are becoming more popular and have passed a learning curve period in Taiwan, has improved transplantation outcomes (unpublished data).

Charlson Comorbidity Index predicts transplantation outcomes in older patients with acute myeloid leukemia and myelodysplastic syndrome

Although reports have shown that age is not a contraindication for allo-HSCT [61,62], the presence of comorbidities may increase overall mortality in patients with hematological malignancies [63]. AML and MDS are the most common hematological malignancies in older patients [64].

The Charlson Comorbidity Index (CCI) has been used since 1987 to estimate the risk of death from comorbid diseases [65]. Chien *et al.* [66] retrospectively analyzed the 2011–2018 TBMTR data on the use of allo-HSCT to treat AML or MDS in patients aged >50 years. They examined patient data in the context of other chronic underlying diseases relevant to the composition of CCI, including myocardial infarction, congestive cardiac insufficiency, peripheral vascular disease, dementia, cerebrovascular disease, chronic pulmonary disease, connective tissue disease, diabetes, and liver disease.

Of 255 patients (median age: 57 years; range: 53–61 years), 38% had CCI scores ≥3. The 1- and 2-year OS rates were 58.8% and 47.6%, respectively. The predictors associated with OS are listed in Table 5. Multivariate analysis identified CCI scores ≥3 (HR: 1.88, 95% CI: 1.31–2.71; $P = 0.001$) and grade III–IV acute GvHD (HR: 3.18, 95% CI: 2.12–4.76; $P < 0.001$) as predictors of poor OS. The 1- and 2-year nonrelapse mortality (NRM) rates were 24.5% and 32%, respectively. Multivariate analysis revealed that CCI scores ≥3 (HR: 1.90, 96% CI: 1.20–3.01; $P = 0.006$) and grade III–IV acute GvHD (HR: 4.91, 95% CI: 3.05–7.92, $P < 0.001$) were significantly correlated with a higher NRM risk.

This cohort study indicates that the use of allo-HSCT should be cautiously considered in older patients with AML or MDS with pretransplantation CCI values ≥3 because of a higher NRM risk.

CONCLUSION

The nationwide activities of HSCT in Taiwan have developed up to international standards. This review demonstrates the significant advancements in HSCT based on data from the TBMTR database, including the incidence and risk of SOS/VOD, the development of a new PTLD scoring system, the incidence and predictors of IPS, stem cell transplantation for the treatment of mantle cell and T-cell lymphoma, autologous transplantation in MM, outcomes of haploidentical transplantation, and the application of the CCI to predict allo-HSCT outcomes in older patients with AML or MDS. Progress in cell therapies, such as chimeric antigen receptor T-cell therapy, should be among the research targets of the next era of advancements in HSCT.

Data availability statement

Data sharing was not applicable to this article as no datasets were generated or analyzed during the current study.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: A global perspective. JAMA 2010;303:1617-24.
2. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: A retrospective observational study. Lancet Haematol 2015;2:e91-100.
3. Annual Report of Blood and Marrow Transplantation Registry, TBMTR; 2022. Available from: https://www.tbmt.org.tw/publicUI/B/B10101. aspx?arg=8DB4B1B7CE6B9EA071. [Last accessed on 2023 Oct 20].
4. Buddhist Tzu Chi Stem Cells Center. Available from: https://btcscc.tzuchi. com.tw/index.php/2022-05-18-08-48-21. [Last accessed on 2023 Oct 20].
5. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000;64:281-91.
6. Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol 2014;4:332-46.
7. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venooclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778-83.
8. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-67.

9. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: Current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2015;50:781-9.

10. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Veno-occlusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology 1994;19:1171-81.

11. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: Incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010;16:157-68.

12. Carreras E, Díaz-Beyá M, Rosiñol L, Martínez C, Fernández-Avilés F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011;17:1713-20.

13. Lee CC, Chang HH, Lu MY, Yang YL, Chou SW, Lin DT, et al. The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan. Ann Hematol 2019;98:745-52.

14. Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm G, Berger F. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol 1995;146:1113-20.

15. Nalesnik MA. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 1998;20:325-42.

16. Dierickx D, Tousseyn T, Gheysens O. How i treat posttransplant lymphoproliferative disorders. Blood 2015;126:2274-83.

17. Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999;94:2208-16.

18. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633-9.

19. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): Risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep 2013;8:173-83.

20. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009;114:4002-8.

21. Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, et al. Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2019;25:1441-9.

22. Lee CC, Hsu TC, Kuo CC, Liu MA, Abdelfattah AM, Chang CN, et al. Validation of a post-transplant lymphoproliferative disorder risk prediction score and derivation of a new prediction score using a national bone marrow transplant registry database. Oncologist 2021;26:e2034-41.

23. Lucena CM, Torres A, Rovira M, Marcos MA, de la Bellacasa JP, Sánchez M, et al. Pulmonary complications in hematopoietic SCT: A prospective study. Bone Marrow Transplant 2014;49:1293-9.

24. Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: A practical approach to diagnosis and treatment. Clin Chest Med 2004;25:189-201.

25. Vande Vusse LK, Madtes DK. Early onset noninfectious pulmonary syndromes after hematopoietic cell transplantation. Clin Chest Med 2017;38:233-48.

26. Ahya VN. Noninfectious acute lung injury syndromes early after hematopoietic stem cell transplantation. Clin Chest Med 2017;38:595-606.

27. Panoskaltsis-Mortari A, Griese M, Madtes DK, Belperio JA, Haddad IY, Folz RJ, et al. An official American Thoracic Society research statement: Noninfectious lung injury after hematopoietic stem cell transplantation: Idiopathic pneumonia syndrome. Am J Respir Crit Care Med 2011;183:1262-79.

28. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26.

29. Sano H, Kobayashi R, Iguchi A, Suzuki D, Kishimoto K, Yasuda K, et al. Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children. Bone Marrow Transplant 2014;49:38-41.

30. Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, et al. High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant 2012;47:1332-7.

31. Afessa B, Abdulai RM, Kremers WK, Hogan WJ, Litzow MR, Peters SG. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. Chest 2012;141:442-50.

32. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;28:425-34.

33. Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, et al. Allogeneic reactivity-mediated endothelial cell complications after HSCT: A plea for consensual definitions. Blood Adv 2019;3:2424-35.

34. Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003;102:2777-85.

35. Liu MA, Lee CC, Phung Q, Dao QL, Tehrani B, Yao M, et al. Incidence and predictors of idiopathic pneumonia syndrome in hematopoietic stem cell transplant patients: A nationwide registry study. Int J Hematol 2022;116:770-7.

36. Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: Progressive shortening in response duration and survival after each relapse. Blood Cancer J 2019;9:50.

37. Jo JC, Kim SJ, Lee HS, Eom HS, Lee SI, Park Y, et al. Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for improving survival of lymphoma report. Ann Hematol 2020;99:223-8.

38. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German high-grade Non-Hodgkin lymphoma study group. Blood 2010;116:3418-25.

39. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d'Etude des lymphomes de l'Adulte. Blood 2013;121:48-53.

40. Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, et al. 15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 2016;175:410-8.

41. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: Retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 2010;45:311-6.

42. Fukano R, Mori T, Kobayashi R, Mitsui T, Fujita N, Iwasaki F, et al. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: A study of children and adolescents in Japan. Br J Haematol 2015;168:557-63.

43. Wang YH, Hsieh CY, Hsiao LT, Lin TL, Liu YC, Yao M, et al. Stem cell transplant for mantle cell lymphoma in Taiwan. Sci Rep 2022;12:5662.

44. Hsu YT, Tsai HJ, Chang JS, Li SS, Tang JL, Yeh SP, et al. Stem cell transplantation for T-cell lymphomas in Taiwan. Bone Marrow Transplant 2018;53:993-1000.

45. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117:6063-73.

46. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in Myeloma. N Engl J Med 2022;387:132-47.

47. Chen JH, Chung CH, Wang YC, Hsu SN, Huang WY, Chien WC. Prevalence and mortality-related factors of multiple Myeloma in Taiwan. PLoS One 2016;11:e0167227.

48. Huang SY, Yao M, Tang JL, Lee WC, Tsay W, Cheng AL, et al. Epidemiology of multiple myeloma in Taiwan: Increasing incidence for the past 25 years and higher prevalence of extramedullary Myeloma in patients younger than 55 years. Cancer 2007;110:896-905.

49. Huang TC, Huang SY, Yao M, Lin CY, Hwang WL, Gau JP, et al. Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan blood and marrow transplantation registry. J Formos Med Assoc 2019;118:471-80.

50. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641-50.

51. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: Results of a prospective phase II trial. Biol Blood Marrow Transplant 2012;18:1859-66.

52. Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B, et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014;20:724-9.

53. Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Kim DD, et al. Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies. Biol Blood Marrow Transplant 2018;24:2259-64.

54. Al Dawsari G, Hassanein MF, Rasheed W, Almohareb F, Chaudhri NA, Alsharif F, et al. Addition of ATG to myeloablative haplo conditioning with post-transplantation cyclophosphamide might decrease the risk of Gvhd and TRM without increasing the risk of relapse. Blood 2016;128:5871.

55. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001;98:3456-64.

56. Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115:3224-30.

57. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107:3065-73.

58. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without *in vitro* T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006;38:291-7.

59. Chang YJ, Huang XJ. Haploidentical stem cell transplantation: Anti-thymocyte globulin-based experience. Semin Hematol 2016;53:82-9.

60. Tsai XC, Chen TT, Gau JP, Wang PN, Liu YC, Lien MY, et al. Outcomes of different haploidentical transplantation strategies from the Taiwan blood and marrow transplantation registry. Cancers (Basel) 2022;14:1097.

61. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute Myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010;28:1878-87.

62. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010;28:405-11.

63. Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S, Smedby KE. The impact of comorbid disease history on all-cause and cancer-specific mortality in Myeloid leukemia and myeloma – A Swedish population-based study. BMC Cancer 2015;15:850.

64. Hassan M, Abedi-Valugerdi M. Hematologic malignancies in elderly patients. Haematologica 2014;99:1124-7.

65. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.

66. Chien SH, Yao M, Li CC, Chang PY, Yu MS, Huang CE, et al. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. J Formos Med Assoc 2021;120:2144-52.